TOURMALINE-MM4: Are There Safety Concerns?

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses safety concerns regarding the trial.

_________

Read here: https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/